GET DAILY SIGNALSBODI Stock: $16 Analyst Target Suggests +255% Upside From Current Levels
Key Takeaways
- The central $16 stock price target is the arithmetic mean of four verified analyst price targets, which average $16.25 before rounding.
- The targets span a wide range from $9 (Roth MKM) to $22 (Noble Financial), reflecting genuine disagreement about the turnaround's durability.
- At a recent close of $4.51, BODI would need to gain roughly 255% to reach $16, a very large move.
- Supporting factors include a shift from multi-level marketing to an omni-channel model, sustained positive EBITDA, and retail expansion tied to the GLP-1 wellness trend.
- Key risks are multi-year revenue declines, a micro-cap valuation of about $33 million, thin trading, and analyst targets that were recently cut.
- Because the stock traded near $16 within the past year, the target is not unprecedented, but it still implies a full multi-year recovery from current levels.
- You can explore this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper detail.
Analyst Price Targets and Consensus View
BODI is the stock of The Beachbody Company, Inc., a Nasdaq-listed fitness and nutrition company. Four current, individually attributable analyst price targets form the basis of the $16 central target. Canaccord Genuity analyst Susan Anderson lowered her target to $16 from $19 in late October 2026 while keeping a Buy rating. Noble Financial maintains a $22 Buy target, Craig-Hallum holds an $18 Buy target, and Roth MKM's George Kelly cut his target to $9 from $13 with a Neutral rating.
The four targets average $16.25, rounded to $16 for readability, with an approximate range of $9 to $22. That wide spread captures a real divide: bullish analysts emphasize the company's turnaround and retail momentum, while the more cautious view focuses on shrinking revenue and a still-fragile growth story. Targets do not represent a guarantee, and the mean should not be read as an official published consensus figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent close of $4.51, BODI carries a market capitalization of roughly $33 million. Reaching $16 would require an advance of approximately 255%, a very large move that would effectively undo most of the stock's steep decline over the past year. The company has shifted from its legacy multi-level marketing structure to an omni-channel, nutrition-led model, achieving positive net income and eleven consecutive quarters of positive adjusted EBITDA. Retail rollouts, including Shakeology at national vitamin retailers and new energy-drink lines, are early demand drivers, but revenue has still contracted sharply on a trailing-twelve-month basis, keeping the path toward $16 dependent on an unproven return to top-line growth.
What Could Support a Move Toward the Target
- Sustained profitability and disciplined cost control, with management reporting multiple quarters of positive adjusted EBITDA.
- Retail and Amazon channel expansion that broadens distribution beyond the legacy direct-selling base.
- Positioning in the wellness and weight-management market, which some analysts tie to rising GLP-1 treatment demand.
- An inexpensive-looking valuation on paper, with a trailing P/E near 2.7 and a price-to-sales ratio near 0.15.
- New product launches, including strength-training and energy-drink lines, that could widen the customer base.
What Could Prevent the Target From Being Reached
- A multi-year revenue decline that has not yet clearly reversed despite improved profitability.
- Micro-cap risk: a small float, low trading volume, and high volatility can amplify price swings in either direction.
- Recent analyst target cuts, including Roth MKM's reduction to $9, signaling skepticism about the pace of recovery.
- Competition in fitness streaming and nutrition from larger, better-capitalized rivals.
- A low Altman Z-score and modest working capital, which keep financial fragility a live concern.
Technical Levels and Market Structure
The 52-week range for BODI is roughly $4.01 to $16.87. The stock now sits near the lower end of that range, above the $4.01 support level, while the $16 target sits just beneath the prior $16.87 high. The 50-day moving average is near $4.78 and the 200-day moving average is near $8.96, meaning the shares trade below both and face meaningful overhead supply on any recovery. Round psychological levels near $5 and the 200-day average around $9 represent the first notable resistance zones on the way toward $16. From what I see, the overhead resistance remains a key factor to monitor closely.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary and no formal timeline is guaranteed. The most important near-term events are quarterly earnings and guidance, with the next report scheduled for November 10, 2026. Investors should watch revenue trends and the nutrition mix, retail sell-through, any changes to analyst targets or ratings, gross-margin performance, and cash and debt levels, all of which could shift the market's view of whether a return toward the $16 objective is plausible.
Final Assessment
The $16 central target for The Beachbody Company represents the average of four verified analyst price targets, rounded from a $16.25 mean, and implies a roughly 255% advance from the recent $4.51 price. The bullish case rests on a genuine operational turnaround, sustained profitability, and retail expansion into the wellness market, while the bearish case points to ongoing revenue declines, analyst target cuts, and the fragility of a micro-cap with a wide $9-to-$22 target range. Reaching $16 would require not only maintaining profitability but proving a durable return to revenue growth. The question of whether BODI can reach that level remains an open, data-dependent one best assessed quarter by quarter.
Using AI for Ongoing Monitoring
I rely on Tickeron's AI Daily Buy/Sell Signals to track shifts in market conditions for names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and broader trends. It serves as a practical complement to fundamental analysis when following volatile micro-cap names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BODI turns positive, indicating new upward trend
BODI saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 88 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BODI's RSI Indicator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where BODI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +2.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where BODI advanced for three days, in 197 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BODI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BODI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BODI entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 24 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.832) is normal, around the industry mean (0.974). P/E Ratio (2.388) is within average values for comparable stocks, (-39.046). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (17.274). Dividend Yield (0.000) settles around the average of (0.979) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (71.888).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BODI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BODI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry InternetSoftwareServices
Advertisement